Plasma Fractionation Market by Product (Albumin, Coagulation Factor Concentrates, Immunoglobulin), Application (Critical Care, Hemato-Oncology, Hematology), End-User - Global Forecast 2024-2030

Plasma Fractionation Market by Product (Albumin, Coagulation Factor Concentrates, Immunoglobulin), Application (Critical Care, Hemato-Oncology, Hematology), End-User - Global Forecast 2024-2030

The Plasma Fractionation Market size was estimated at USD 35.52 billion in 2023 and expected to reach USD 38.95 billion in 2024, at a CAGR 10.45% to reach USD 71.27 billion by 2030.

Plasma fractionation refers to collecting, separating, and purifying various essential components present in human plasma, primarily including albumin, immunoglobulins, coagulation factors, and other proteins. These components have many applications in medical treatments, such as hemophilia therapy, immunity disorders treatment, wound healing support, neurology therapy, and other rare diseases. The demand for source plasma has been steadily increasing due to its role as a vital ingredient in several life-saving therapies. This surge can be attributed to an aging population prone to chronic illnesses requiring blood-based therapies and the rising prevalence of immune disorders. In addition, rising awareness about blood-related diseases among patients contributes significantly to this market's expansion. However, stringent government regulations on plasma fractionation and the presence of alternative recombinant therapies may hamper the market demand. New advancements in production technology further boost opportunities for the players involved in this field. Moreover, strategic collaborations among various stakeholders drive innovative research work within the industry that provides novel solutions and is expected to create a lucrative market opportunity in the forecasted period.

Regional Insights

The Americas has a significant market presence in the plasma fractionation market due to a well-established healthcare infrastructure, high prevalence of immunodeficiency diseases, and an increasing geriatric population. In Europe, EU countries have a strong regulatory framework governing the plasma fractionation industry. The European Medicines Agency (EMA) regulates manufacturing practices and oversees quality standards for blood-derived products, significantly driving the region's market demand. The MEA region presents lucrative opportunities due to rising incomes and expanding access to healthcare services. The Asia-Pacific observed a developing landscape in the plasma fractionation market owing to rapid urbanization and economic development that is driving investments in healthcare infrastructure. Additionally, there is an increasing focus on blood safety regulations by governments in the APAC region, presenting opportunities for market players.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Plasma Fractionation Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

Improving access to plasma-based therapies and high use of immunoglobulins in various therapeutic areas
Government initiatives to increase plasma collection
Growing prevalence of elderly people around the globe and the increasing number of blood collection facilities

Market Restraints

Presence of new pathogenic agents that resist the present viral inactivation treatments

Market Opportunities

Continuous advancements in process development technology for improved formulations
Exponential utilization in new clinical trials and growing R&D activities in plasma treatment

Market Challenges

Stringent government regulations on plasma fractionation and the presence of alternative recombinant therapies

Market Segmentation Analysis

Product: Rising use of plasma fractionation for immunoglobulins purification
Application: Proliferating use to treat hematological disorders
End-User: Extensive use of plasma fractionation in clinical research laboratories to ensure the safety and efficacy of plasma-derived products

Market Disruption Analysis

Porter’s Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Plasma Fractionation Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Plasma Fractionation Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Grifols Egypt delivers first plasma medicines made from Egyptian plasma donations

Grifols, a producer of plasma-derived medicines, has partnered with Egypt's National Service Projects Organization (NSPO) to inaugurate their first plasma-derived medicines. These medicines are manufactured using donations from Egypt, ensuring a reliable and sustainable source. The shipment includes vital plasma therapies such as albumin, which is utilized in major surgeries, trauma treatment, and severe burn cases. Additionally, immunoglobulins (Ig) are included for immunodeficiencies, along with blood-clotting factors to manage bleeding disorders.

CSL's USD470 Million Plasma Fractionation Facility Opens in Marburg, Germany

CSL, a biotechnology company, recently celebrated the inauguration of its state-of-the-art plasma fractionation facility in Marburg, Germany. This monumental project, with a budget of USD 470 million, spanned five years and has quadrupled the company's manufacturing capacity for producing life-saving medicines derived from donated human plasma. The new facility, leveraging optimized process flows, cutting-edge technologies, and advanced automation, has significantly enhanced operational efficiency.

Takeda to Invest 100 Billion JPY in a New Manufacturing Facility for Plasma-Derived Therapies in Japan

Takeda is making a significant investment of approximately 100 billion yen to construct a state-of-the-art manufacturing facility in Osaka, Japan. This facility is expected to be the largest and specialized in the production of plasma-derived therapies in the country. The investment aligns with Takeda's capital allocation policy, which aims to create value and establish a world-class end-to-end manufacturing facility for PDTs at its Juso, Osaka plant.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Plasma Fractionation Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Plasma Fractionation Market, highlighting leading vendors and their innovative profiles. These include 3M Company, ADMA Biologics, Inc., Bharat Serums and Vaccines Limited, Bio Products Laboratory Ltd., Biotest AG by Grifols, S.A., China Biologic Products, Inc., CSL Limited, Emergent BioSolutions Inc., Fusion Health Care Pvt. Ltd., GC Biopharma corp., Grifols, S.A., HEINKEL Process Technology GmbH, Hemarus Therapeutics Ltd, Intas Pharmaceuticals Ltd., Kamada Ltd., Kedrion S.p.A., LFB SA, Merck KGaA, Octapharma AG, PlasmaGen BioSciences Pvt. Ltd., Prothya Biosolutions B.V., Sanquin, Shanghai Raas Blood Products Co. Ltd, SK Plasma Co.,Ltd., STERIS plc, and Takeda Pharmaceutical Company Ltd.

Market Segmentation & Coverage

This research report categorizes the Plasma Fractionation Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
Albumin
Coagulation Factor Concentrates
Factor IX
Factor VIII
Factor XIII
Fibrinogen Concentrates
Prothrombin Complex Concentrate
Von Willebrand Factor
Immunoglobulin
Intravenous Immunoglobulin
Subcutaneous Immunoglobulin
Protease Inhibitors
Application
Critical Care
Hemato-Oncology
Hematology
Neurology
Pulmonology
Rheumatology
End-User
Academic & Research Institutes
Clinical Research Laboratories
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

Please Note: PDF & Excel + Online Access - 1 Year